Nordic Capital Invests in Leo Pharma

Nordic Capital has invested in medical dermatology company, Leo Pharma, becoming an active minority owner and partner to the Leo Foundation.

Global healthcare private equity investor, Nordic Capital, has invested in medical dermatology company, Leo Pharma, becoming an active minority owner and partner to the Leo Foundation.

According to a March 23, 2021 press release, Nordic Capital’s investment will be used to support Leo Pharma in strengthening its position in medical dermatology and help speed up innovation and growth. The €450 million (US $532 million) investment from Nordic Capital in partnership with the Leo Foundation, which remains the company’s majority shareholder, will back Leo Pharma’s 2030 strategy to become a global leader in medical dermatology.

“The partnership with Nordic Capital is a strong confirmation that Leo Pharma is an exceptional company with a valuable heritage in topical dermatology that has clear potential to grow into a leader in innovative therapies,” said Jesper Mailind, CEO of the Leo Foundation, in the press release. “I am very enthusiastic about the opportunity to welcome Nordic Capital onboard. With Nordic Capital we have secured a supportive and seasoned partner going forward with deep medical expertise and a strong track record supporting value creation in innovative healthcare businesses globally.”

“We could not be more pleased that Nordic Capital is partnering with the Leo Foundation and Leo Pharma,” added Jonas Agnblad, partner, co-head of Healthcare, Nordic Capital Advisors, in the press release. “Dermatology is one of the fastest growing therapeutic areas within pharmaceuticals. We see scientific advances addressing significant unmet needs in the coming years, resulting in tremendous value for patients and healthcare systems.”

“I am delighted to welcome Nordic Capital as our new co-owner and partner in our ambitious endeavors to make Leo Pharma a global leader in medical dermatology,” commented Catherine Mazzacco, CEO of Leo Pharma, in the press release. “I am confident that we, with our new ownership model, have paved the way for further acceleration of our strong growth ambitions, and that this will enable us to further strengthen our dedication to dermatology, with a sustained focus on building a strong pipeline and innovating across science and technology to the benefit of patients.”

Source: Nordic Capital